Abstract: The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to IBD (e.g. Crohn's Disease) and/or their response to a particular drug or drugs.
Abstract: The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to ADHD disease and/or their response to a particular drug or drugs.
Type:
Application
Filed:
February 6, 2008
Publication date:
May 13, 2010
Applicant:
GENIZON BIOSCIENCES INC.
Inventors:
Abdelmajid Belouchi, Vanessa Bruat, Pascal Croteau, Daniel Dubois, Randall David Little, Bruno Paquin, John Verner Raelson, Jonathan Segal, Paul Van Eerdewegh, Sandie Briand, Sem Kebache, Tim Keith
Abstract: The present invention relates to the ATG16l1 gene and genetic variants associated with Crohn's disease. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to Crohn's disease and/or their response to a particular drug or drugs.
Type:
Application
Filed:
July 26, 2007
Publication date:
April 22, 2010
Applicant:
GENIZON BIOSCIENCES INC
Inventors:
John Verner Raelson, Stefan Schreiber, Randall David Little, Andre Franke, Jochen Hampe, Tim Keith, Vanessa Bruat, Abdelmajid Belouchi